Your source for the latest medtech news from AdvaMed® and our members.
WASHINGTON, D.C.—Scott Whitaker, president and CEO of AdvaMed, the medtech association, made the following comment on the collaboration between Revival Healthcare Capital and Olympus Corporation to co-found Swan EndoSurgical, Inc. to…
WASHINGTON, D.C.—Scott Whitaker, president and CEO of AdvaMed, the medtech association, issued the following statement on the White House’s “America’s AI Action Plan”:
Washington, DC.—AdvaMed, the medtech association, asked the Court of Appeals for the Third Circuit to vacate the judgment of the District Court, which if allowed to stand, would have significant…
Swedish MedTech company Multi4 Medical, chaired by renowned investor Erik Selin, has received FDA clearance for its patented technology for automated cancer treatment. The decision means that Multi4 is now…
If you have media inquiries, please contact:
Jim Jeffries, Senior Vice President, Public Affairs, 206-225-5226
GRENOBLE, France & MINNEAPOLIS, Minnesota (July 17, 2025) – UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), received investigational device exemption (IDE) approval from…
WOBURN, Mass. (July 7, 2025) – Sirtex Medical (“Sirtex”), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug Administration (FDA) approved SIR-Spheres® Y-90 resin…
WOBURN, Mass. (July 7, 2025) – Sirtex Medical (“Sirtex”), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug Administration (FDA) approved SIR-Spheres® Y-90 resin…
WASHINGTON – Today, AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker on the impact the “One Big Beautiful Bill Act” will have on medtech…
Brought to you by AdvaMed®, Medtech POV with Scott Whitaker is a podcast that covers the intersection of medtech and policy from every perspective.
Levallois-Perret, France – May 22, 2025 — Cardiawave SA, medtech company specialized in valvular heart disease, presented today at the EuroPCR Congress the 12-month results from its “Valvosoft® FIM Study”…